Related Experiment Video
Updated: Sep 28, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
A clinicopathologic and immunohistochemical study of diffuse large B-cell lymphoma
Kun Tao1, Xiongzeng Zhu, Weiling Xu
1Department of Pathology, Cancer Hospital, Fudan University, Shanghai 200032, China.
Insights
This study analyzed diffuse large B-cell lymphoma (DLBCL) using clinicopathologic and immunohistochemical features. Immunohistochemistry is valuable for DLBCL diagnosis and differential diagnosis, aiding in understanding its aggressive nature.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Accurate diagnosis and subtyping are crucial for effective treatment strategies.
Purpose of the Study:
- To investigate the clinicopathologic and immunohistochemical characteristics of DLBCL.
- To assess the utility of immunohistochemistry in the diagnosis and differential diagnosis of DLBCL.
Main Methods:
- Sixty DLBCL cases were analyzed.
- Immunohistochemical staining was performed for LCA, L26, BLA-36, CD30, and bcl-6 using the EnVision 2-step method.
Main Results:
- The majority of patients (76.7%) were aged 40-70 years.
- Histopathologic morphology was predominantly centroblastic (88.3%).
- Immunohistochemistry revealed high positivity for LCA, L26, and BLA36 (100%), with 95% expressing bcl-6.
Conclusions:
- DLBCL exhibits cytologic variability and is an aggressive lymphoma.
- Pathologic features and immunohistochemistry are practical tools for DLBCL diagnosis.
- Immunohistochemistry aids in diagnosis but does not delineate distinct morphologic subtypes.
Objective:
To study the clinicopathologic and immunohistochemical features of diffuse large B-cell lymphoma (DLBCL) and the significance of immunohistochemistry in diagnosis and differential diagnosis of DLBCL.
Methods:
60 cases of DLBCL were studied and immunohistochemical staining for LCA, L26, BLA-36, CD30, bcl-6 were carried out with the EnVision 2 step method.
Results:
The age range of 76.7% (46/60) patients was 40 - 70 years. The location of the lesion includes nodal and extranodal sites. 90.0% (54/60) were in clinical stages of II (24/54), III (21/54), IV (9/54). Histopathologic morphology presented as centroblastic (88.3%, 53/60), immunoblastic (3.3%, 2/60), anaplastic large B cell type (3.3%, 2/60) and T cell rich B cell type (5.0%, 3/60). Immunostaining showed 100% (60/60) DLBCL were positive for LCA, L26, BLA36, 3.3% (2/60) DLBCL positive for CD30, 95% (57/60) expressed bcl-6 protein.
Conclusions:
DLBCL is an aggressive lymphoma which shows cytologic variability from case to case. The evaluation of pathologic features and immunohistochemistry in DLBCL are useful and practical for diagnostic purposes, but cannot delineate distinctive morphologic subtypes.
